Windlas Biotech Ltd Q2FY26 | ₹2,223.98 Mn Revenue, ₹177.9 Mn PAT — Complex Generics Ki Simple Kahani with 17% ROCE and Almost Zero Debt
1. At a Glance
Windlas Biotech Ltd (NSE: WINDLAS) is one of those rare pharma players that’s almost debt-free, genuinely profitable, and still under the radar — the financial equivalent of that topper who never attends college fests. As of Q2FY26, the company posted revenue of ₹2,223.98 million, PAT of ₹177.9 million, and an EBITDA margin of 13%. Annualised, that’s a cool ₹8,896 million top line and ₹712 million bottom line. With a market cap of ₹1,831 crore, P/E of 27.2x, and ROCE of 17%, Windlas trades at a valuation that says “we’re serious about money, but not Divi’s Labs serious.”
In short: solid growth, steady margins, minimal debt of just ₹31.2 crore, and promoter holding at 62% — Windlas Biotech looks like the accountant’s favourite child of the pharmaceutical sector. But does the clean balance sheet hide a spicy backstory? Let’s find out.
2. Introduction
Welcome to the curious case of Windlas Biotech, where complex generics meet simple arithmetic and the CDMO model meets Indian jugaad. Headquartered in Dehradun, this company quietly makes medicines for half of India’s pharma giants — from Pfizer to Intas, Sanofi, and Cadila — without hogging the limelight itself. Think of it as Bollywood’s ghost singer who belts out hits while the hero lip-syncs on-screen.
In a world where most pharma companies fight over patents, Windlas has built its empire by manufacturing for others — a business model that’s as lucrative as it is low-key. The best part? It makes the complex generics that drive margins higher than the average paracetamol manufacturer.
Despite a sluggish broader pharma market, Windlas has grown 19% in sales YoY, 13% in profit YoY, and maintained its 13% operating margin in Q2FY26. In a sector full of volatile molecules, Windlas’ numbers are the pharmaceutical version of yoga — consistent, calm, and slightly boring (but profitable).
So what makes this ₹1,800-crore smallcap so interesting? Simple — it’s building a high-margin injectables empire, cutting dependence on big clients, and exporting complex generics to regulated markets.
3. Business Model – WTF Do They Even Do?
Windlas Biotech is basically your neighborhood pharma factory with brains. It operates under three main segments:
Generic Formulations CDMO (75% of H1FY25 revenue) The company is a contract developer and manufacturer (CDMO). Think of it as the TCS of tablets — big pharma outsources product development and manufacturing, while Windlas does all the heavy lifting. It owns 99% of product IPs, serving 583 customers including 7 of India’s top 10 pharma companies. The star of the show? Complex generics — medicines that are tough to copy but essential for chronic diseases like diabetes, cardiovascular, and neuropsychiatry. These high-margin products form 64% of FY24’s portfolio.
Trade Generics & Institutional (21%) Windlas also supplies low-cost generics to 996+ distributors across 29 states, and to government institutions under schemes like Jan Aushadhi Yojana. Basically, while the CDMO division courts Pfizer and Sanofi, this division flirts with Bharat’s rural hospitals.
Exports (4%) Currently small but growing faster than a teenager’s Wi-Fi usage. Windlas exports 69 products to semi-regulated and regulated markets, with certifications from SAPHRA (South Africa) and EU-GMP (Europe). Plans for USFDA approval are also underway.
Its five WHO-GMP-compliant plants in Dehradun together crank out 7.3 billion tablets/capsules and 54 million sachets per year. The company is also commissioning an Injectables Facility (Plant-V) that’s expected to start contributing revenue from Q3FY25 — the pharma world’s equivalent of adding a rocket booster to your scooter.
4. Financials Overview
Here’s how Windlas performed this quarter — numbers so balanced they’d make even a yoga guru proud:
Source table
Metric
Q2FY26 (Latest)
Q2FY25 (YoY)
Q1FY26 (QoQ)
YoY %
QoQ %
Revenue (₹ Cr)
222.4
187.0
210.0
18.9%
5.9%
EBITDA (₹ Cr)
29.0
23.0
27.0
26.1%
7.4%
PAT (₹ Cr)
17.8
15.7
17.9
13.4%
-0.5%
EPS (₹)
8.45
7.49
8.43
12.8%
0.2%
Annualised EPS = ₹33.8, giving a P/E of ~25.7x on CMP ₹870. Not cheap, not crazy — somewhere between Dr. Reddy’s rationality and Mankind’s optimism.
Commentary: Windlas’ revenue and profit growth have both been healthy, with consistent OPM at 13%. EBITDA rising faster than revenue shows margin discipline — a rare trait in contract manufacturing. The only worry? PAT has plateaued QoQ — but hey, maybe even profits need a nap.
5. Valuation Discussion – Fair Value Range Only
Let’s get numerical.
a) P/E Method:
EPS (Annualised): ₹33.8
Reasonable P/E Range: 22x – 30x (based on peers and growth visibility) → Fair Value Range = ₹744 – ₹1,014
b) EV/EBITDA Method:
EV = ₹1,847 Cr
EBITDA (TTM): ₹123 Cr
EV/EBITDA = 15x (current) Industry average = 13–17x → Fair Value Range ≈ ₹1,700 – ₹2,100 Cr Market Cap Equivalent per-share value = ₹800 – ₹990
c) DCF (Simplified): Assume:
Revenue growth 12% CAGR next 5 yrs
FCF margin 7%
WACC 11%, Terminal growth 3% → Intrinsic Value ≈ ₹870–₹930 per share
🎯 Combined Fair Value Range (Educational only): ₹780 – ₹980/share.
Disclaimer: This fair value range is for educational purposes only and is not investment advice. Consult your own inner auditor before acting on it.
6. What’s Cooking – News, Triggers, Drama
Windlas is entering its glow-up phase. The injectables plant (Plant-V) is the biggest trigger — commissioned recently and GMP-certified. That means ampoules, liquid vials, and lyophilized
